Cointime

Xenikos

company

About

Xenikos is developing a combination of two toxin-loaded anti-T-cell antibodies.

  • 1 - 10

Highlights

Total Funding Amount
€45.50M
Funding Rounds
4
Investors
4

Details

Last Funding Type
Grant
Industries
Biotechnology,Life Science,Therapeutics
Founded date
Jan 1, 2009
Number Of Employee
1 - 10
Operating Status
Active

Xenikos aims to develop a new medicine, based on the action of antibodies that enables patients suffering serious immune diseases, or rejection after transplantation, to reset their immune system quickly and efficiently. Xenikos strives to develop new, innovative immunotherapy medicines to help restore patients’ health and save lives.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
€45.50M
Xenikos has raised a total of €45.50M in funding over 2 rounds. Their latest funding was raised on Dec 19, 2022 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 19, 2022 Grant — 1 European Innovation Council — Detail
Sep 8, 2021 Convertable Note €40M 1 — — Detail
Jun 19, 2012 Debt Financing €1.90M 1 Agentschap NL — Detail
Jun 19, 2012 Series A €3.60M 2 — — Detail

Investors

Number of Lead Investors
Number of Investors
2
4
Xenikos is funded by 4 investors. European Innovation Council and Agentschap NL are the most recent investors.
Investor Name Lead Investor Funding Round
European Innovation Council Yes Grant
Agentschap NL Yes Debt Financing
Sanquin Blood Supply Foundation — Convertable Note
Innovation & Investment Fund Gelderland — Series A
Cointime
เนื้อหา
บริษัท